A Phase 2/3 interventional study of mRNA-1273 and Placebo in SARS-CoV-2, sponsored by ModernaTX, Inc.. Completed at 91 sites in 2 countries. Open to participants aged 6 Months to 11 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-13.
Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 2/3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19 — 2 open to participants now, 5 under way, 1 of them phase 3. 2019-nCoV Vaccine mRNA-1273 · COVID-19.
Among the 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19, this one is the 4th largest by enrollment, is one of 21 that started in 2021, is one of 4 in phase 2/3, and was the 9th registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →2 of the 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19 are open now, in 1 country. Recruiting first, the newest first:
ModernaTX, Inc. · Sites in United States
Ages 12+ · Healthy volunteers
ModernaTX, Inc. · Sites in United States
Ages 6 mo+ · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 6 Months to 11 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 14 · Phase 3 14 · Phase 4 7
First in 2020; this study’s year is marked. 21 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 11,942 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 499 across the 36 interventional studies. Of the 24 that completed or were terminated, 16 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 36 have an industry lead sponsor. The 10 most frequent:
This study is registered under ModernaTX, Inc., one of the names counted as Moderna, Inc.. Under that name alone:
ModernaTX, Inc. is the lead sponsor of 119 studies on the registry; 18 are open to participants now.
Of its 64 completed or terminated interventional studies of FDA-regulated products, 35 (55%) have results posted.
34 studies in COVID-19 by Moderna, Inc.: 3 open now, 6 under way, none of them phase 3. Of 28 finished, 11 (39%) have results posted.
Among the 34 studies in COVID-19 by Moderna, Inc., this one is the 4th largest by enrollment of the 22 interventional ones that give a count, is one of 8 that started in 2021, is one of 4 in phase 2/3, and was the 4th registered.
Moderna, Inc.’s COVID-19 studies by the year they started, since 2020.
3 of the studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07863635ModernaTX, Inc.A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Formulations | 2026-12-11 |
| NCT06585241ModernaTX, Inc.A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations | 2026-12-31 |
| NCT07266558ModernaTX, Inc.A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19) | 2027-06-16 |
Add all 3 to your calendar (.ics) → With an account.
Among the 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19, from their registry updates:
Among Moderna, Inc.’s 34 in COVID-19:
This tab as a report to print or save as PDF → With an account.
The primary goal for this study is to evaluate up to 3 dose levels of mRNA-1273 vaccine given to healthy children as intramuscular (IM) injection in 2 doses (in Parts 1 and 2) and 3 doses (in Part 3), and a third dose or an optional booster dose (BD) (in Parts 1 and 2).
This is a Phase 2/3, 3-part, open-label, dose-escalation, age de-escalation, randomized, observer-blind, placebo-controlled, expansion study intended to infer the effectiveness of mRNA-1273 in children aged 6 months to less than 12 years.
Please access http://www.kidcovestudy.com for additional information, such as Study Overview, Participation, Site Locations along with contact numbers for each location for the study.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
This study's enrollment of 11,942 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Browse COVID-19 studies →ModernaTX, Inc. is the lead sponsor of 119 studies on the registry; 18 are open to participants now.
Of its 64 completed or terminated interventional studies of FDA-regulated products, 35 (55%) have results posted.
Compared within COVID-19, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Coronavirus Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part 1: Participants will receive 2 IM injections of mRNA-1273 at doses pre-specified for this study, on Days 1 and 29. Participants will be offered an optional BD of mRNA-1273 lower than the dose chosen for primary series, ≥6 months after Dose 2. After protocol amendment (PA) 9, participants who have not yet received a BD will be offered a BD with mRNA-1273.214. Part 2: Participants will receive 2 IM injections of mRNA-1273 at dose selected from Part 1 on Days 1 and 29. Participants (6 to \<12 year) will be offered an optional BD of mRNA-1273 lower than the dose chosen for primary series, ≥6 months after Dose 2. After PA 9, participants who have not yet received a BD will be offered a BD with mRNA-1273.214. Part 3: Participants will receive 2 IM injections of mRNA-1273 on Days 1 and 29 as primary series then 1 IM injection as Dose 3, on Day 149 ≥3 months and ≤5 months after receipt of Dose 2 of primary series. All 3 injections will be administered at lower dose than that of Part 1.
Biological: mRNA-1273 · Biological: mRNA-1273.214
Part 2 only: Participants will receive 2 IM injections of mRNA-1273-matching placebo on Day 1 and Day 29. Participants (6 to \<12 year old) will be offered an optional BD of mRNA-1273 at a dose lower than the dose that was chosen for the primary series for this age group, at least 6 months post-cross-over Dose 2. After PA 9, participants who have not yet received a BD will be offered a BD with mRNA-1273.214.
Biological: mRNA-1273 · Biological: Placebo · Biological: mRNA-1273.214
Sterile liquid for injection
0.9% sodium chloride (normal saline) injection
Sterile liquid for injection
Parts 1, 2, and 3: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)
Solicited ARs were collected in an electronic diary (eDiary). Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered adverse events (AEs). Investigator reviewed whether the solicited AR was also to be recorded as an AE. A Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
Time frame: 7 days post-vaccination
Parts 1, 2, and 3: Number of Participants With Unsolicited AEs
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. COVID-19/SARS-CoV-2 infections were considered clinical events for efficacy and not AEs. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section and presented by each dose group separately.
Time frame: Up to 28 days post-vaccination
Parts 1, 2, and 3: Number of Participants With Serious Adverse Events (SAEs), AEs of Special Interest (AESIs), Medically Attended AEs (MAAEs), and AEs Leading to Discontinuation From Study
An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability, was a congenital anomaly/birth defect, or was an important medical event. AESIs for mRNA-1273 were identified based upon medical concepts that may be related to COVID-19 or were of interest in COVID-19 vaccine safety surveillance. An MAAE is an AE that led to an unscheduled visit to a healthcare practitioner. This included visits to a study site for unscheduled assessments and visits to healthcare practitioners external to the study site. COVID-19/SARS-CoV-2 infections were considered clinical events for efficacy and not AEs. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section and presented by each dose group separately.
Time frame: Up to 2 years
Parts 1 and 2: Geometric Mean (GM) Value of Serum Pseudovirus Neutralizing Antibody ID50 Titers From Study mRNA-1273-P204 (P204) Vaccine Recipients at Day 57 Compared With Those From Young Adult (18 to 25 Years) Vaccine Recipients (Day 57) in Study P301
Antibody values reported as below lower limit of quantification (LLOQ) were replaced by 0.5\*LLOQ and values greater than upper limit of quantification (ULOQ) were replaced by ULOQ if actual values were not available. LLOQ was 18.5 arbitrary units (AU)/milliliter (mL) and ULOQ was 45118 AU/mL for ID50 titer. Per-Protocol (PP) Immunogenicity Subset: all enrolled participants who received planned doses of the study vaccine per schedule, had baseline SARS-CoV-2 status, had baseline and Day 57 antibody assessment for analysis endpoint, complied with immunogenicity window based on 2nd injection timing; had negative reverse transcriptase polymerase chain reaction (RT-PCR) test for SARS-CoV-2 and negative serology test based on binding antibody (bAb) specific to SARS-CoV-2 nucleocapsid protein at baseline, not receiving highly active antiretroviral therapy (HAART) for participants with HIV; and had no major protocol deviations that impacted key or critical data.
Time frame: Day 57 P204/Day 57 P301
Parts 2 and 3: GM Concentration of Serum Pseudovirus Neutralizing Antibody VAC62 From Study P204 Vaccine Recipients at Day 57 Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P301
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ and values \>ULOQ were replaced by ULOQ if actual values were not available. LLOQ was 10 AU/mL and ULOQ was 111433 AU/mL. PP Immunogenicity Subset: all enrolled participants who received planned doses of the study vaccine per schedule, had baseline SARS-CoV-2 status, had baseline and Day 57 antibody assessment, complied with immunogenicity window based on 2nd injection timing; had negative RT-PCR test for SARS-CoV-2 and negative serology test based on bAb specific to SARS-CoV-2 nucleocapsid protein at baseline in Part 2, not receiving HAART in participants with HIV; and had no major protocol deviations that impacted key/critical data. Since the number of participants enrolled in Part 3 was substantially smaller than the planned sample size required for immunogenicity hypothesis testing after Dose 2 of mRNA-1273 25 μg primary series and after a 3rd dose of mRNA-1273 25 μg, the hypothesis testing was not performed.
Time frame: Day 57 P204/Day 57 P301
Parts 1 and 2: Seroresponse Rate (SRR) For Serum Pseudovirus Neutralizing Antibody ID50 From Study P204 Vaccine Recipients at Day 57 Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P301
Percentage of participants with seroresponse for pseudovirus neutralizing antibody ID50 are reported. Seroresponse: change from below LLOQ to equal above 4\*LLOQ, or at least a 4-fold rise if baseline is ≥LLOQ. LLOQ=18.5 AU/mL and ULOQ=45118 AU/mL for ID50 titer. PP Immunogenicity Subset: all enrolled participants who received planned doses of study vaccine, had baseline SARS-CoV-2 status, had baseline and Day 57 antibody assessment, complied with immunogenicity window based on 2nd injection timing; had negative RT-PCR test for SARS-CoV-2 and negative serology test based on bAb specific to SARS-CoV-2 at baseline, not receiving HAART; and had no major protocol deviations that impacted key/critical data. Since the number of participants enrolled in Part 3 was substantially smaller than the planned sample size required for immunogenicity hypothesis testing after Dose 2 of mRNA-1273 25 μg primary series and after a 3rd dose of mRNA-1273 25 μg, the hypothesis testing was not performed.
Time frame: Day 57 P204/Day 57 P301
Parts 2 and 3: SRR For Serum Pseudovirus Neutralizing Antibody VAC62 From Study P204 Vaccine Recipients at Day 57 Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P301
Percentage of participants with seroresponse for Pseudovirus Neutralizing Antibody VAC62 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 10 and ULOQ AU/mL was 111433 AU/mL. PP Immunogenicity Subset: all enrolled participants who received planned doses of the study vaccine per schedule, had baseline SARS-CoV-2 status, had baseline and Day 57 antibody assessment for analysis endpoint, complied with immunogenicity window based on 2nd injection timing; had negative RT-PCR test for SARS-CoV-2 and negative serology test based on bAb specific to SARS-CoV-2 nucleocapsid protein at baseline in Part 2, not receiving HAART in participants with HIV; and had no major protocol deviations that impacted key or critical data.
Time frame: Day 57 P204/Day 57 P301
Parts 1 and 2: GM Concentration of Post-booster Dose Serum Pseudovirus Neutralizing Antibody VAC62 in Study P204 Compared With Post-primary Series (Post-Dose 2) in Young Adult (18 to 25 Years of Age) Vaccine Recipients in Study P301
Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ and values greater than the ULOQ were replaced by ULOQ if actual values were not available. LLOQ was 10 AU/mL and ULOQ was 111433 AU/mL. PP Immunogenicity Subset (Booster Dose Analysis): all enrolled participants who received 2 doses of planned doses of mRNA-1273 vaccination in Part 1 open-label phase or Part 2 blinded phase per schedule, received booster dose in Booster Dose Analysis, not receiving HAART in participants with HIV, had a negative SARS-CoV-2 status at baseline (pre-dose 1 of mRNA-1273), had BD-Day 29 Ab assessment for the analysis endpoint, no major protocol deviations that impacted key or critical data, and had not received off-study COVID-19 vaccination prior to BD-Day 29 visit.
Time frame: BD-Day 29 P204/Day 57 P301
Part 3: GM Concentration of Post-third Dose Serum Pseudovirus Neutralizing Antibody VAC62 in Study P204 Compared With Post-primary Series (Post-Dose 2) in Young Adult (18 to 25 Years) Vaccine Recipients in Study P301
Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ and values greater than the ULOQ were replaced by ULOQ if actual values were not available. LLOQ was 10 AU/mL and ULOQ was 111433 AU/mL. PP Immunogenicity Subset (Third Dose Analysis): all enrolled participants who received first 2 doses of planned doses of mRNA-1273 vaccination in Part 3 open-label phase per schedule, received third dose in Third Dose Analysis, not receiving HAART in participants with HIV, had BD-Day 29 antibody assessment for the analysis endpoint, had no major protocol deviations that impacted key or critical data, and had not received off-study COVID-19 vaccination prior to BD-Day 29 visit. Since the number of participants enrolled in Part 3 was substantially smaller than the planned sample size required for immunogenicity hypothesis testing after Dose 2 of mRNA-1273 25 μg primary series and after a 3rd dose of mRNA-1273 25 μg, the hypothesis testing was not performed.
Time frame: Third Dose-Day 29 P204/Day 57 P301
Parts 1 and 2: SRR for Post-booster Dose Serum Pseudovirus Neutralizing Antibody VAC62 From Baseline (Pre-Dose 1) Compared With Post-primary Series (Post-Dose 2) From Baseline (Pre-Dose 1) in Young Adult (18 to 25 Years) Vaccine Recipients in Study P301
Percentage of participants with seroresponse for Pseudovirus Neutralizing Antibody VAC62 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 10 AU/mL and ULOQ was 111433 AU/mL. PP Immunogenicity Subset (Booster Dose Analysis): all enrolled participants who received 2 doses of planned doses of mRNA-1273 vaccination in Part 1 open-label phase or Part 2 blinded phase per schedule, received booster dose in Booster Dose Analysis, not receiving HAART in participants with HIV, had a negative SARS-CoV-2 status at baseline (pre-dose 1 of mRNA-1273), had BD-Day 29 Ab assessment for the analysis endpoint, no major protocol deviations that impacted key or critical data, and had not received off-study COVID-19 vaccination prior to BD-Day 29 visit.
Time frame: BD-Day 29 P204/Day 57 P301
Part 3: SRR for Post-third Dose Serum Pseudovirus Neutralizing Antibody VAC62 From Baseline (Pre-Dose 1) Compared With Post-primary Series (Post-Dose 2) From Baseline (Pre-Dose 1) in Young Adult (18 to 25 Years) Vaccine Recipients in Study P301
Percentage of participants with seroresponse for Pseudovirus Neutralizing Antibody VAC62 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 10 AU/mL and ULOQ was 111433 AU/mL. PP Immunogenicity Subset (Third Dose Analysis): all enrolled participants who received first 2 doses of planned doses of mRNA-1273 vaccination in Part 3 open-label phase per schedule, received third dose in Third Dose Analysis, not receiving HAART in participants with HIV were not receiving HAART, had BD-Day 29 antibody assessment for the analysis endpoint, had no major protocol deviations that impacted key or critical data, and had not received off-study COVID-19 vaccination prior to BD-Day 29 visit.
Time frame: Third Dose-Day 29 P204/Day 57 P301
Parts 1 and 2: GM Level of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) S Protein-specific Binding Antibody (bAb), as Measured by MesoScale Discovery (MSD) Electrochemiluminescence (ECL) Multiplex Assay on Days 1 and 57
GM level of SARSCOV2S2P immunoglobulin G (IgG) antibody VAC123/VAC72, as measured by ECL multiplex assay specific to SARS-CoV-2 spike protein is reported. Antibody values reported as \<LLOQ were replaced by 0.5\*LLOQ and values \>ULOQ were replaced by ULOQ if actual values were not available. LLOQ was 23 AU/mL and ULOQ was 14000000 AU/mL for VAC72. LLOQ was 69 AU/mL and ULOQ was 14400000 AU/mL for VAC123. PP Immunogenicity Subset: all enrolled participants who received planned doses of study vaccine per schedule, had baseline SARS-CoV-2 status, had baseline and Day 57 antibody assessment, complied with immunogenicity window based on 2nd injection timing; had negative RT-PCR test for SARS-CoV-2 and negative serology test based on bAb specific to SARS-CoV-2 protein at baseline, not receiving HAART in participants with HIV; and had no major protocol deviations.
Time frame: Day 1, Day 57 (1 month after Dose 2)
Parts 1 and 2: GM Level of SARS-CoV-2 S Protein-specific bAb, as Measured by MSD ECL Multiplex Assay on Baseline (Pre-dose 1), Day 57, Day 209, BD-Day 1, and BD-Day 29
GM level of SARSCOV2S2P IgG antibody VAC123/VAC72 is reported. Antibody values reported as \<LLOQ were replaced by 0.5\*LLOQ and values \>ULOQ were replaced by ULOQ if actual values were not available. LLOQ was 23 and ULOQ was 14000000 AU/mL for VAC72. LLOQ was 69 and ULOQ was 14400000 AU/mL for VAC123. PP Immunogenicity Subset (Booster Dose Analysis): all enrolled participants who received 2 doses of planned doses of mRNA-1273 in Part 1 open-label phase or Part 2 blinded phase per schedule, received booster dose in Booster Dose Analysis, , not receiving HAART in participants with HIV, had a negative SARS-CoV-2 status at baseline, had BD-Day 29 antibody assessment for the analysis endpoint, no major protocol deviations that impacted key or critical data, and had not receive off-study COVID-19 vaccination prior to BD-Day 29 visit.
Time frame: Baseline (Pre-dose 1), Day 57, Day 209, BD-Day 1 (Pre-booster), BD-Day 29 (1 month after booster dose)
Part 3: GM Level of SARS-CoV-2 S Protein-specific bAb, as Measured by MSD ECL Multiplex Assay on Baseline (Pre-dose 1), Day 57, Third Dose-Day 1, Third Dose-Day 29, Third Dose-Day 181
GM level of SARSCOV2S2P IgG antibody against B.1.1.529 strain is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ and values greater than the ULOQ were replaced by ULOQ if actual values were not available. LLOQ was 102 and ULOQ was 1180000 AU/mL for VAC123. PP Immunogenicity Subset (Third Dose Analysis): all enrolled participants who received first 2 doses of planned doses of mRNA-1273 vaccination in Part 3 open-label phase per schedule, received third dose in Third Dose Analysis, participants with HIV were not receiving HAART, had BD-Day 29 antibody assessment for the analysis endpoint, had no major protocol deviations that impact key or critical data, and had not receive off-study COVID-19 vaccination prior to BD-Day 29 visit.
Time frame: Baseline (Pre-dose 1), Day 57, Third Dose-Day 1, Third Dose-Day 29, Third Dose-Day 181
Parts 1 and 2: GM Value of SARS-CoV-2-specific Neutralizing Antibody ID50 Titers on Day 1 and Day 57
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ and values greater than ULOQ were replaced by ULOQ if actual values were not available. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer. PP Immunogenicity Subset: all enrolled participants who received planned doses of the study vaccine per schedule, had baseline SARS-CoV-2 status, had baseline and Day 57 antibody assessment for analysis endpoint, complied with immunogenicity window based on 2nd injection timing; had negative RT-PCR test for SARS-CoV-2 and negative serology test based on bAb specific to SARS-CoV-2 nucleocapsid protein at baseline, not receiving HAART in participants with HIV; and had no major protocol deviations that impacted key or critical data.
Time frame: Day 1 and Day 57 (1 month after Dose 2)
Parts 2 and 3: GM Concentration of SARS-CoV-2-specific Neutralizing Antibody VAC62 on Day 1 and Day 57
Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ and values greater than the ULOQ were replaced by ULOQ if actual values were not available. LLOQ was 10 AU/mL and ULOQ was 111433 AU/mL. Data are reported per Baseline SARS-CoV-2 status: Negative and Positive. PP Immunogenicity Subset: all enrolled participants who received planned doses of the study vaccine per schedule, had baseline SARS-CoV-2 status, had baseline and Day 57 antibody assessment for analysis endpoint, complied with immunogenicity window based on 2nd injection timing; had negative RT-PCR test for SARS-CoV-2 and negative serology test based on bAb specific to SARS-CoV-2 nucleocapsid protein at baseline in Part 2, not receiving HAART in participants with HIV; and had no major protocol deviations that impacted key or critical data.
Time frame: Day 1 and Day 57 (1 month after Dose 2)
Parts 1 and 2: GM Concentration of Post-booster SARS-CoV-2-specific Neutralizing Antibody VAC62 on Baseline, Day 57, Day 209, BD-Day 1, and BD-Day 29
Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ and values greater than the ULOQ were replaced by ULOQ if actual values were not available. LLOQ was 10 AU/mL and ULOQ was 111433 AU/mL. PP Immunogenicity Subset (Booster Dose Analysis): all enrolled participants who received 2 doses of planned doses of mRNA-1273 vaccination in Part 1 open-label phase or Part 2 blinded phase per schedule, received booster dose in Booster Dose Analysis, not receiving HAART in participants with HIV, had a negative SARS-CoV-2 status at baseline (pre-dose 1 of mRNA-1273), had BD-Day 29 Ab assessment for the analysis endpoint, no major protocol deviations that impacted key or critical data, and had not received off-study COVID-19 vaccination prior to BD-Day 29 visit.
Time frame: Baseline (Pre-Dose 1), Day 57 (1 month after Dose 2), Day 209 (6 months after Dose 2), BD-Day 1 (Pre-booster), and BD-Day 29 (1 month after booster dose or third dose)
Part 3: GM Concentration of Post-third Dose SARS-CoV-2-specific Neutralizing Antibody VAC62 on Baseline, Day 57, Third Dose-Day 1, Third Dose-Day 29, and Third Dose-Day 181
Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ and values greater than the ULOQ were replaced by ULOQ if actual values were not available. LLOQ was 10 AU/mL and ULOQ was 111433 AU/mL. PP Immunogenicity Subset (Third Dose Analysis): all enrolled participants who received first 2 doses of planned doses of mRNA-1273 vaccination in Part 3 open-label phase per schedule, received third dose in Third Dose Analysis, not receiving HAART in participants with HIV, had BD-Day 29 antibody assessment for the analysis endpoint, had no major protocol deviations that impacted key or critical data, and had not received off-study COVID-19 vaccination prior to BD-Day 29 visit.
Time frame: Baseline (Pre-Dose 1), Day 57 (1 month after Dose 2), Third Dose-Day 1 (at least 3 months or 6 months after Dose 2), Third Dose-Day 29 (1 month after third dose), and Third Dose-Day 181 (6 months after third dose)
Part 2: Number of Participants With SARS-CoV-2 Infection Including Symptomatic and Asymptomatic Infection (by Serology and/or RT-PCR)
SARS-CoV-2 infection was defined in participants with negative SARS-CoV-2 at baseline: bAb level against SARS-CoV-2 nucleocapsid protein negative at Day 1, that became positive (as measured by Roche Elecsys) postbaseline; OR positive RT-PCR postbaseline. PP Set for Efficacy included all enrolled participants who received planned doses of study drug per schedule, complied with the 2nd injection timing, had no major protocol deviations that impacted key or critical efficacy data, and had a negative RT-PCR test for SARS-CoV-2 and negative serology test based on bAb specific to SARS-CoV-2 nucleocapsid protein at baseline.
Time frame: 14 days after second injection
Part 2: Number of Participants With Asymptomatic SARS-CoV-2 Infection, Measured by RT-PCR and/or bAb Levels Against SARS-CoV-2 Nucleocapsid Protein (by Roche Elecsys)
Asymptomatic SARS-CoV-2 infection was identified by absence of symptoms and infections as detected by RT-PCR or serology tests: Absence of COVID-19 symptoms AND at least 1 from following: bAb level against SARS-CoV-2 nucleocapsid protein negative at Day 1 that became positive post-baseline, OR positive RT-PCR test post-baseline. PP Set for Efficacy included all enrolled participants who received planned doses of study drug per schedule, complied with the 2nd injection timing, had no major protocol deviations that impacted key or critical efficacy data, and had a negative RT-PCR test for SARS-CoV-2 and negative serology test based on bAb specific to SARS-CoV-2 nucleocapsid protein at baseline.
Time frame: 14 days after second injection
Part 2: Number of Participants With Occurrence of COVID-19 (Per US Centers for Disease Control and Prevention [CDC] Case Definition of COVID-19)
A COVID-19 case was identified as a positive post-baseline RT-PCR test result together with at least 1 of following systemic symptoms: fever (≥ 38 degrees Celsius \[°C\]/≥ 100.4 degree Fahrenheit \[°F\]) or chills, fatigue, headache, myalgia, nasal congestion or rhinorrhea, new loss of taste or smell, sore throat, abdominal pain, diarrhoea, nausea/vomiting, poor appetite/poor feeding; or at least 1 of following respiratory signs/symptoms: cough, shortness of breath or difficulty breathing. PP Set for Efficacy included all enrolled participants who received planned doses of study drug per schedule, complied with the 2nd injection timing, had no major protocol deviations that impacted key or critical efficacy data, and had a negative RT-PCR test for SARS-CoV-2 and negative serology test based on bAb specific to SARS-CoV-2 nucleocapsid protein at baseline.
Time frame: 14 days after second injection
Number of Deaths Related to Study Drug
A death that occurred during the study or that came to the attention of the investigator during the study was reported to the Sponsor, whether or not it was considered related to study drug. The investigator assessed causality (that is, whether there is a reasonable possibility that the study drug caused the death). The relationship was characterized using the following classifications: Not related: There was not a reasonable possibility of a relationship to the study drug. The temporal sequence of the death relative to administration of the study drug was not reasonable AND/OR the death was more likely explained by a cause other than the study drug. Related: There was a reasonable possibility of a relationship to the study drug. There was evidence of exposure to the study drug. The temporal sequence of the death relative to the administration of the study drug was reasonable. The death was more likely explained by the study drug than by another cause.
Time frame: Up to 2 years
The study was conducted in 3 parts: Part 1 (open-label; dose-escalation and age de-escalation), Part 2 (placebo-controlled), and Part 3 (open-label; lower dose regimen).
| Milestone | Part 1 (6-11 Years): mRNA-1273 50 µg | Part 1 (6-11 Years): mRNA-1273 100 µg | Part 1 (2-5 Years): mRNA-1273 25 µg | Part 1 (2-5 Years): mRNA-1273 50 µg | Part 1 (6-23 Months): mRNA-1273 25 µg | Part 2 (6-11 Years): Placebo | Part 2 (6-11 Years): mRNA-1273 50 µg | Part 2 (2-5 Years): Placebo | Part 2 (2-5 Years): mRNA-1273 25 µg | Part 2 (6-23 Months): Placebo | Part 2 (6-23 Months): mRNA-1273 25 µg | Part 3 (6-11 Years): Primary Series mRNA-1273 25 µg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 380 | 371 | 75 | 149 | 150 | 1004 | 3011 | 1008 | 3040 | 669 | 1995 | 90 |
| Received first injection | 380 | 371 | 75 | 149 | 150 | 997 | 3005 | 1007 | 3031 | 667 | 1993 | 90 |
| Received second injection | 379 | 371 | 75 | 149 | 150 | 974 | 2995 | 984 | 3007 | 649 | 1979 | 84 |
| Received first injection in open-label | 0 | 0 | 0 | 0 | 0 | 702 | 0 | 640 | 0 | 444 | 0 | 0 |
| Received booster dose | 230 | 249 | 40 | 99 | 125 | 469 | 2002 | 282 | 1301 | 237 | 1016 | 70 |
| Received crossover vaccination | 0 | 0 | 0 | 0 | 0 | 702 | 0 | 640 | 0 | 444 | 0 | 0 |
| Completed | 307 | 316 | 55 | 131 | 105 | 556 | 2329 | 515 | 2086 | 366 | 1387 | 51 |
| Not completed | 73 | 55 | 20 | 18 | 45 | 448 | 682 | 493 | 954 | 303 | 608 | 39 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 0 |
| Withdrew: Lost to follow-up | 24 | 15 | 6 | 4 | 21 | 55 | 237 | 52 | 221 | 43 | 142 | 18 |
| Withdrew: Received emergency use authorization (eua) vaccine | 5 | 4 | 0 | 3 | 1 | 194 | 37 | 222 | 29 | 115 | 9 | 1 |
| Withdrew: Physician decision | 1 | 0 | 0 | 0 | 0 | 3 | 18 | 1 | 7 | 0 | 5 | 0 |
| Withdrew: Withdrawal by subject | 36 | 31 | 11 | 8 | 16 | 162 | 299 | 149 | 303 | 94 | 192 | 16 |
| Withdrew: Other than specified | 6 | 5 | 3 | 2 | 6 | 31 | 86 | 66 | 388 | 48 | 258 | 4 |
| Withdrew: Protocol deviation | 0 | 0 | 0 | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 0 | 0 |
| Withdrew: Missing | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 2 | 1 | 1 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
Solicited ARs were collected in an electronic diary (eDiary). Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered adverse events (AEs). Investigator reviewed whether the solicited AR was also to be recorded as an AE. A Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
| Participants | Part 1 (6-11 Years): PS mRNA-1273 50 μg - BD 25 μg | Part 1 (6-11 Years): PS mRNA-1273 100 μg - BD 25 μg | Part 1 (6-23 Months): PS mRNA-1273 25 μg - BD 10 μg | Part 1 (2-5 Years): PS mRNA-1273 25 μg - BD 10 μg | Part 1 (2-5 Years): PS mRNA-1273 50 μg - BD 10 μg | Part 1 (2-5 Years): PS mRNA-1273 25 μg - BD 25 μg | Part 1 (2-5 Years): PS mRNA-1273 50 μg - BD 25 μg | Part 2 (6 Months-5 Yrs): PS PBO - mRNA-1273 25 μg - BD 25 μg | Part 2 (6 Months-5 Years): PS mRNA-1273 25 μg - BD 25 μg | Part 2(6-11 Yrs): PS Placebo - mRNA-1273 50 μg - BD 1273 25 μg | Part 2 (6-11 Years): PS mRNA-1273 50 μg - BD 1273 25 μg | Part 3 (6-11 Years): BD mRNA-1273 25 µg | Part 1 (6-11 Years): mRNA-1273 50 µg | Part 1 (6-11 Years): mRNA-1273 100 µg | Part 1 (2-5 Years): mRNA-1273 25 µg | Part 1 (2-5 Years): mRNA-1273 50 µg | Part 1 (6-23 Months): mRNA-1273 25 µg | Part 2 (6-11 Years): Placebo | Part 2 (6-11 Years): mRNA-1273 50 µg | Part 2 (2-5 Years): Placebo | Part 2 (2-5 Years): mRNA-1273 25 µg | Part 2 (6-23 Months): Placebo | Part 2 (6-23 Months): mRNA-1273 25 µg | Part 3 (6-11 Years): mRNA-1273 25 µg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Parts 1, 2, and 3: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) | 216 | 221 | 93 | 24 | 46 | 7 | 36 | 4 | 12 | 358 | 1726 | 30 | 374 | 367 | 62 | 147 | 141 | 823 | 2983 | 797 | 2800 | 596 | 1889 | 66 |
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. COVID-19/SARS-CoV-2 infections were considered clinical events for efficacy and not AEs. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section and presented by each dose group separately.
| Participants | Part 1 (6-11 Years): PS mRNA-1273 50 μg - BD 25 μg | Part 1 (6-11 Years): PS mRNA-1273 100 μg - BD 25 μg | Part 1 (6-23 Months): PS mRNA-1273 25 μg - BD 10 μg | Part 1 (2-5 Years): PS mRNA-1273 25 μg - BD 10 μg | Part 1 (2-5 Years): PS mRNA-1273 50 μg - BD 10 μg | Part 1 (2-5 Years): PS mRNA-1273 25 μg - BD 25 μg | Part 1 (2-5 Years): PS mRNA-1273 50 μg - BD 25 μg | Part 2 (6 Months-5 Yrs): PS PBO - mRNA-1273 25 μg - BD 25 μg | Part 2 (6 Months-5 Years): PS mRNA-1273 25 μg - BD 25 μg | Part 2(6-11 Yrs): PS Placebo - mRNA-1273 50 μg - BD 1273 25 μg | Part 2 (6-11 Years): PS mRNA-1273 50 μg - BD 1273 25 μg | Part 1 (6-11 Years): mRNA-1273 50 µg | Part 1 (6-11 Years): mRNA-1273 100 µg | Part 1 (2-5 Years): mRNA-1273 25 µg | Part 1 (2-5 Years): mRNA-1273 50 µg | Part 1 (6-23 Months): mRNA-1273 25 µg | Part 2 (6-11 Years): mRNA-1273 50 µg | Part 2 (2-5 Years): mRNA-1273 25 µg | Part 2 (6-23 Months): mRNA-1273 25 µg | Part 3 (6-11 Years): mRNA-1273 25 µg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Parts 1, 2, and 3: Number of Participants With Unsolicited AEs | 38 | 20 | 24 | 8 | 4 | 1 | 8 | 1 | 5 | 33 | 196 | 106 | 92 | 15 | 51 | 75 | 785 | 1087 | 883 | 17 |
An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability, was a congenital anomaly/birth defect, or was an important medical event. AESIs for mRNA-1273 were identified based upon medical concepts that may be related to COVID-19 or were of interest in COVID-19 vaccine safety surveillance. An MAAE is an AE that led to an unscheduled visit to a healthcare practitioner. This included visits to a study site for unscheduled assessments and visits to healthcare practitioners external to the study site. COVID-19/SARS-CoV-2 infections were considered clinical events for efficacy and not AEs. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section and presented by each dose group separately.
| Participants | Part 1 (6-11 Years): PS mRNA-1273 50 μg - BD 25 μg | Part 1 (6-11 Years): PS mRNA-1273 100 μg - BD 25 μg | Part 1 (6-23 Months): PS mRNA-1273 25 μg - BD 10 μg | Part 1 (2-5 Years): PS mRNA-1273 25 μg - BD 10 μg | Part 1 (2-5 Years): PS mRNA-1273 50 μg - BD 10 μg | Part 1 (2-5 Years): PS mRNA-1273 25 μg - BD 25 μg | Part 1 (2-5 Years): PS mRNA-1273 50 μg - BD 25 μg | Part 2 (6 Months-5 Yrs): PS PBO - mRNA-1273 25 μg - BD 25 μg | Part 2 (6 Months-5 Years): PS mRNA-1273 25 μg - BD 25 μg | Part 2(6 M-5 Yr): PS PBO - mRNA-1273 25 μg - BD 1273.214 10 μg | Part 2(6 Months-5 Yrs): PS mRNA-1273 25 μg - BD 1273.214 10 μg | Part 2(6 M-5 Yr): PS PBO - mRNA-1273 25 μg - BD 1273.214 25 μg | Part 2(6 Months-5 Yrs): PS mRNA-1273 25 μg - BD 1273.214 25 μg | Part 2(6-11 Yrs): PS Placebo - mRNA-1273 50 μg - BD 1273 25 μg | Part 2 (6-11 Years): PS mRNA-1273 50 μg - BD 1273 25 μg | Part 2(6-11 Yrs): PS PBO - mRNA-1273 50 μg - BD 1273.214 25 μg | Part 2 (6-11 Years): PS mRNA-1273 50 μg - BD 1273.214 25 μg | Part 1 (6-11 Years): mRNA-1273 50 µg | Part 1 (6-11 Years): mRNA-1273 100 µg | Part 1 (2-5 Years): mRNA-1273 25 µg | Part 1 (2-5 Years): mRNA-1273 50 µg | Part 1 (6-23 Months): mRNA-1273 25 µg | Part 2 (6-11 Years): mRNA-1273 50 µg | Part 2 (2-5 Years): mRNA-1273 25 µg | Part 2 (6-23 Months): mRNA-1273 25 µg | Part 3 (6-11 Years): mRNA-1273 25 µg | Part 2(6-11 Yrs): PS PBO - mRNA-1273 50 μg (Crossover) | Part 2 (2-5 Years): PS PBO - mRNA-1273 25 μg (Crossover) | Part 2 (6-23 Months): PBO - mRNA-1273 25 μg (Crossover) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SAEs | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 7 | 16 | 0 | 0 | 3 | 7 | 0 | 0 | 5 | 3 | 0 | 0 | 3 | 22 | 32 | 45 | 1 | 3 | 8 | 4 |
| AESIs | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 2 | 9 | 0 | 0 | 5 | 7 | 0 | 1 | 2 | 19 | 13 | 13 | 0 | 3 | 1 | 1 |
| MAAEs | 85 | 71 | 59 | 16 | 23 | 4 | 17 | 3 | 10 | 182 | 901 | 1 | 3 | 137 | 616 | 16 | 34 | 175 | 169 | 32 | 80 | 105 | 1095 | 1687 | 1237 | 22 | 221 | 204 | 171 |
| AEs Leading to Discontinuation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
Antibody values reported as below lower limit of quantification (LLOQ) were replaced by 0.5\*LLOQ and values greater than upper limit of quantification (ULOQ) were replaced by ULOQ if actual values were not available. LLOQ was 18.5 arbitrary units (AU)/milliliter (mL) and ULOQ was 45118 AU/mL for ID50 titer. Per-Protocol (PP) Immunogenicity Subset: all enrolled participants who received planned doses of the study vaccine per schedule, had baseline SARS-CoV-2 status, had baseline and Day 57 antibody assessment for analysis endpoint, complied with immunogenicity window based on 2nd injection timing; had negative reverse transcriptase polymerase chain reaction (RT-PCR) test for SARS-CoV-2 and negative serology test based on binding antibody (bAb) specific to SARS-CoV-2 nucleocapsid protein at baseline, not receiving highly active antiretroviral therapy (HAART) for participants with HIV; and had no major protocol deviations that impacted key or critical data.
| titer | Part 1 (2-5 Years): mRNA-1273 25 µg | Part 1 (2-5 Years): mRNA-1273 50 µg | Part 1 (6-23 Months): mRNA-1273 25 µg | Part 1 (6-11 Years): mRNA-1273 50 µg | Part 1 (6-11 Years): mRNA-1273 100 µg | Part 2 (6-11 Years): mRNA-1273 50 µg | Study mRNA-1273-P301 (NCT04470427) mRNA-1273 100 μg |
|---|---|---|---|---|---|---|---|
| Parts 1 and 2: Geometric Mean (GM) Value of Serum Pseudovirus Neutralizing Antibody ID50 Titers From Study mRNA-1273-P204 (P204) Vaccine Recipients at Day 57 Compared With Those From Young Adult (18 to 25 Years) Vaccine Recipients (Day 57) in Study P301 | 1012.5 (848.2 to 1208.6) | 1845.9 (1600.5 to 2128.9) | 1782.6 (1542.0 to 2060.7) | 1669.1 (1504.5 to 1851.6) | 1890.2 (1603.8 to 2227.7) | 1618.3 (1460.0 to 1793.9) | 1321.9 (1196.5 to 1460.5) |
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ and values \>ULOQ were replaced by ULOQ if actual values were not available. LLOQ was 10 AU/mL and ULOQ was 111433 AU/mL. PP Immunogenicity Subset: all enrolled participants who received planned doses of the study vaccine per schedule, had baseline SARS-CoV-2 status, had baseline and Day 57 antibody assessment, complied with immunogenicity window based on 2nd injection timing; had negative RT-PCR test for SARS-CoV-2 and negative serology test based on bAb specific to SARS-CoV-2 nucleocapsid protein at baseline in Part 2, not receiving HAART in participants with HIV; and had no major protocol deviations that impacted key/critical data. Since the number of participants enrolled in Part 3 was substantially smaller than the planned sample size required for immunogenicity hypothesis testing after Dose 2 of mRNA-1273 25 μg primary series and after a 3rd dose of mRNA-1273 25 μg, the hypothesis testing was not performed.
| AU/mL | Part 2 (2-5 Years): mRNA-1273 25 µg | Part 2 (6-23 Months): mRNA-1273 25 µg | Part 3 (6-11 Years): Primary Series mRNA-1273 25 µg | Study mRNA-1273-P301 (NCT04470427) mRNA-1273 100 μg |
|---|---|---|---|---|
| Parts 2 and 3: GM Concentration of Serum Pseudovirus Neutralizing Antibody VAC62 From Study P204 Vaccine Recipients at Day 57 Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P301 | 1394.1 (1267.7 to 1533.1) | 1759.8 (1606.7 to 1927.4) | 4368.6 (3339.6 to 5714.6) | 1400.4 (1272.7 to 1541.0) |
Percentage of participants with seroresponse for pseudovirus neutralizing antibody ID50 are reported. Seroresponse: change from below LLOQ to equal above 4\*LLOQ, or at least a 4-fold rise if baseline is ≥LLOQ. LLOQ=18.5 AU/mL and ULOQ=45118 AU/mL for ID50 titer. PP Immunogenicity Subset: all enrolled participants who received planned doses of study vaccine, had baseline SARS-CoV-2 status, had baseline and Day 57 antibody assessment, complied with immunogenicity window based on 2nd injection timing; had negative RT-PCR test for SARS-CoV-2 and negative serology test based on bAb specific to SARS-CoV-2 at baseline, not receiving HAART; and had no major protocol deviations that impacted key/critical data. Since the number of participants enrolled in Part 3 was substantially smaller than the planned sample size required for immunogenicity hypothesis testing after Dose 2 of mRNA-1273 25 μg primary series and after a 3rd dose of mRNA-1273 25 μg, the hypothesis testing was not performed.
| percentage of participants | Part 1 (6-11 Years): mRNA-1273 50 µg | Part 1 (6-11 Years): mRNA-1273 100 µg | Part 1 (2-5 Years): mRNA-1273 25 µg | Part 1 (2-5 Years): mRNA-1273 50 µg | Part 1 (6-23 Months): mRNA-1273 25 µg | Part 2 (6-11 Years): mRNA-1273 50 µg | Study mRNA-1273-P301 (NCT04470427) mRNA-1273 100 μg |
|---|---|---|---|---|---|---|---|
| Parts 1 and 2: Seroresponse Rate (SRR) For Serum Pseudovirus Neutralizing Antibody ID50 From Study P204 Vaccine Recipients at Day 57 Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P301 | 99.5 (97.3 to 99.9) | 100 (93.6 to 100.0) | 100 (92.9 to 100) | 100 (94.7 to 100.0) | 100 (96.2 to 100.0) | 99.0 (97.2 to 99.8) | 99.3 (97.6 to 99.9) |
Percentage of participants with seroresponse for Pseudovirus Neutralizing Antibody VAC62 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 10 and ULOQ AU/mL was 111433 AU/mL. PP Immunogenicity Subset: all enrolled participants who received planned doses of the study vaccine per schedule, had baseline SARS-CoV-2 status, had baseline and Day 57 antibody assessment for analysis endpoint, complied with immunogenicity window based on 2nd injection timing; had negative RT-PCR test for SARS-CoV-2 and negative serology test based on bAb specific to SARS-CoV-2 nucleocapsid protein at baseline in Part 2, not receiving HAART in participants with HIV; and had no major protocol deviations that impacted key or critical data.
| percentage of participants | Part 2 (2-5 Years): mRNA-1273 25 µg | Part 2 (6-23 Months): mRNA-1273 25 µg | Part 3 (6-11 Years): Primary Series mRNA-1273 25 µg | Study mRNA-1273-P301 (NCT04470427) mRNA-1273 100 μg |
|---|---|---|---|---|
| Parts 2 and 3: SRR For Serum Pseudovirus Neutralizing Antibody VAC62 From Study P204 Vaccine Recipients at Day 57 Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P301 | 98.9 (96.9 to 99.8) | 100 (98.6 to 100.0) | 88.5 (77.8 to 95.3) | 99.3 (97.6 to 99.9) |
Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ and values greater than the ULOQ were replaced by ULOQ if actual values were not available. LLOQ was 10 AU/mL and ULOQ was 111433 AU/mL. PP Immunogenicity Subset (Booster Dose Analysis): all enrolled participants who received 2 doses of planned doses of mRNA-1273 vaccination in Part 1 open-label phase or Part 2 blinded phase per schedule, received booster dose in Booster Dose Analysis, not receiving HAART in participants with HIV, had a negative SARS-CoV-2 status at baseline (pre-dose 1 of mRNA-1273), had BD-Day 29 Ab assessment for the analysis endpoint, no major protocol deviations that impacted key or critical data, and had not received off-study COVID-19 vaccination prior to BD-Day 29 visit.
| AU/mL | Study mRNA-1273-P301 (NCT04470427) mRNA-1273 100 μg | BD Phase Part 1 (6 Month-5 Yrs): PS mRNA-1273 25 μg - BD 10 μg | BD Part 1 and 2 (6-11 Yrs): PS mRNA-1273 50 μg - BD 1273 25 μg |
|---|---|---|---|
| Parts 1 and 2: GM Concentration of Post-booster Dose Serum Pseudovirus Neutralizing Antibody VAC62 in Study P204 Compared With Post-primary Series (Post-Dose 2) in Young Adult (18 to 25 Years of Age) Vaccine Recipients in Study P301 | 1400.4 (1272.7 to 1541.0) | 5457.2 (4525.7 to 6580.3) | 5575.9 (5026.8 to 6184.9) |
Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ and values greater than the ULOQ were replaced by ULOQ if actual values were not available. LLOQ was 10 AU/mL and ULOQ was 111433 AU/mL. PP Immunogenicity Subset (Third Dose Analysis): all enrolled participants who received first 2 doses of planned doses of mRNA-1273 vaccination in Part 3 open-label phase per schedule, received third dose in Third Dose Analysis, not receiving HAART in participants with HIV, had BD-Day 29 antibody assessment for the analysis endpoint, had no major protocol deviations that impacted key or critical data, and had not received off-study COVID-19 vaccination prior to BD-Day 29 visit. Since the number of participants enrolled in Part 3 was substantially smaller than the planned sample size required for immunogenicity hypothesis testing after Dose 2 of mRNA-1273 25 μg primary series and after a 3rd dose of mRNA-1273 25 μg, the hypothesis testing was not performed.
| AU/mL | Part 3 (6-11 Years): BD mRNA-1273 25 µg | Study mRNA-1273-P301 (NCT04470427) mRNA-1273 100 μg |
|---|---|---|
| Part 3: GM Concentration of Post-third Dose Serum Pseudovirus Neutralizing Antibody VAC62 in Study P204 Compared With Post-primary Series (Post-Dose 2) in Young Adult (18 to 25 Years) Vaccine Recipients in Study P301 | 4616.6 (3669.4 to 5808.3) | 1400.4 (1272.7 to 1541.0) |
Percentage of participants with seroresponse for Pseudovirus Neutralizing Antibody VAC62 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 10 AU/mL and ULOQ was 111433 AU/mL. PP Immunogenicity Subset (Booster Dose Analysis): all enrolled participants who received 2 doses of planned doses of mRNA-1273 vaccination in Part 1 open-label phase or Part 2 blinded phase per schedule, received booster dose in Booster Dose Analysis, not receiving HAART in participants with HIV, had a negative SARS-CoV-2 status at baseline (pre-dose 1 of mRNA-1273), had BD-Day 29 Ab assessment for the analysis endpoint, no major protocol deviations that impacted key or critical data, and had not received off-study COVID-19 vaccination prior to BD-Day 29 visit.
| percentage of participants | Study mRNA-1273-P301 (NCT04470427) mRNA-1273 100 μg | BD Phase Part 1 (6 Month-5 Yrs): PS mRNA-1273 25 μg - BD 10 μg | BD Part 1 and 2 (6-11 Yrs): PS mRNA-1273 50 μg - BD 1273 25 μg |
|---|---|---|---|
| Parts 1 and 2: SRR for Post-booster Dose Serum Pseudovirus Neutralizing Antibody VAC62 From Baseline (Pre-Dose 1) Compared With Post-primary Series (Post-Dose 2) From Baseline (Pre-Dose 1) in Young Adult (18 to 25 Years) Vaccine Recipients in Study P301 | 99.3 (97.6 to 99.9) | 100 (95.0 to 100.0) | 100 (97.2 to 100.0) |
Percentage of participants with seroresponse for Pseudovirus Neutralizing Antibody VAC62 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 10 AU/mL and ULOQ was 111433 AU/mL. PP Immunogenicity Subset (Third Dose Analysis): all enrolled participants who received first 2 doses of planned doses of mRNA-1273 vaccination in Part 3 open-label phase per schedule, received third dose in Third Dose Analysis, not receiving HAART in participants with HIV were not receiving HAART, had BD-Day 29 antibody assessment for the analysis endpoint, had no major protocol deviations that impacted key or critical data, and had not received off-study COVID-19 vaccination prior to BD-Day 29 visit.
| percentage of participants | Part 3 (6-11 Years): BD mRNA-1273 25 µg | Study mRNA-1273-P301 (NCT04470427) mRNA-1273 100 μg |
|---|---|---|
| Part 3: SRR for Post-third Dose Serum Pseudovirus Neutralizing Antibody VAC62 From Baseline (Pre-Dose 1) Compared With Post-primary Series (Post-Dose 2) From Baseline (Pre-Dose 1) in Young Adult (18 to 25 Years) Vaccine Recipients in Study P301 | 90.0 (78.2 to 96.7) | 99.3 (97.6 to 99.9) |
GM level of SARSCOV2S2P immunoglobulin G (IgG) antibody VAC123/VAC72, as measured by ECL multiplex assay specific to SARS-CoV-2 spike protein is reported. Antibody values reported as \<LLOQ were replaced by 0.5\*LLOQ and values \>ULOQ were replaced by ULOQ if actual values were not available. LLOQ was 23 AU/mL and ULOQ was 14000000 AU/mL for VAC72. LLOQ was 69 AU/mL and ULOQ was 14400000 AU/mL for VAC123. PP Immunogenicity Subset: all enrolled participants who received planned doses of study vaccine per schedule, had baseline SARS-CoV-2 status, had baseline and Day 57 antibody assessment, complied with immunogenicity window based on 2nd injection timing; had negative RT-PCR test for SARS-CoV-2 and negative serology test based on bAb specific to SARS-CoV-2 protein at baseline, not receiving HAART in participants with HIV; and had no major protocol deviations.
| AU/mL | Part 1 (6-11 Years): mRNA-1273 50 µg | Part 1 (6-11 Years): mRNA-1273 100 µg | Part 1 (2-5 Years): mRNA-1273 25 µg | Part 1 (2-5 Years): mRNA-1273 50 µg | Part 1 (6-23 Months): mRNA-1273 25 µg | Part 2 (6-11 Years): mRNA-1273 50 µg | Part 2 (2-5 Years): mRNA-1273 25 µg | Part 2 (6-23 Months): mRNA-1273 25 µg |
|---|---|---|---|---|---|---|---|---|
| Baseline (Day 1) | 35.6 (31.0 to 40.8) | 49.1 (33.9 to 71.1) | 15.8 (13.5 to 18.5) | 33.7 (26.2 to 43.4) | 14.6 (12.8 to 16.7) | 32.6 (28.5 to 37.3) | 24.5 (21.7 to 27.5) | 22.0 (19.1 to 25.3) |
| Day 57 | 325784.0 (302917.7 to 350376.4) | 457349.2 (402424.0 to 519770.8) | 261952.0 (227935.8 to 301044.7) | 417419.8 (359399.2 to 484807.0) | 297561.7 (234740.9 to 377194.3) | 293118.9 (261748.3 to 328249.4) | 235059.2 (198610.2 to 278197.3) | 293955.4 (256077.7 to 337435.8) |
GM level of SARSCOV2S2P IgG antibody VAC123/VAC72 is reported. Antibody values reported as \<LLOQ were replaced by 0.5\*LLOQ and values \>ULOQ were replaced by ULOQ if actual values were not available. LLOQ was 23 and ULOQ was 14000000 AU/mL for VAC72. LLOQ was 69 and ULOQ was 14400000 AU/mL for VAC123. PP Immunogenicity Subset (Booster Dose Analysis): all enrolled participants who received 2 doses of planned doses of mRNA-1273 in Part 1 open-label phase or Part 2 blinded phase per schedule, received booster dose in Booster Dose Analysis, , not receiving HAART in participants with HIV, had a negative SARS-CoV-2 status at baseline, had BD-Day 29 antibody assessment for the analysis endpoint, no major protocol deviations that impacted key or critical data, and had not receive off-study COVID-19 vaccination prior to BD-Day 29 visit.
| AU/mL | Part 1 (6-11 Years): PS mRNA-1273 50 μg - BD 25 μg | Part 1 (6-23 Months): PS mRNA-1273 25 μg - BD 10 μg | Part 1 (2-5 Years): PS mRNA-1273 25 μg - BD 10 μg | Part 2 (6-11 Years): PS mRNA-1273 50 μg - BD 1273 25 μg |
|---|---|---|---|---|
| Baseline | 50.0 (42.7 to 58.6) | 37.5 (34.3 to 40.9) | 34.5 (NA to NA) | 51.9 (44.6 to 60.3) |
| Day 57 | 302128.3 (266991.2 to 341889.7) | 279427.6 (242953.8 to 321377.2) | 241874.9 (180565.7 to 324001.0) | 336189.6 (257789.9 to 438432.5) |
| Day 209 | 74516.9 (63553.5 to 87371.5) | 66516.5 (59365.2 to 74529.2) | 71427.5 (50801.5 to 100427.9) | 85360.1 (71680.4 to 101650.5) |
| BD-Day 1 | 66677.7 (52382.4 to 84874.2) | 68322.4 (53860.8 to 86667.0) | 50621.5 (34112.1 to 75121.2) | 86416.4 (72836.0 to 102528.9) |
| BD-Day 29 | 633999.7 (561311.4 to 716101.0) | 675348.1 (584405.3 to 780443.0) | 536478.9 (403508.2 to 713268.2) | 520973.0 (469812.4 to 577704.8) |
GM level of SARSCOV2S2P IgG antibody against B.1.1.529 strain is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ and values greater than the ULOQ were replaced by ULOQ if actual values were not available. LLOQ was 102 and ULOQ was 1180000 AU/mL for VAC123. PP Immunogenicity Subset (Third Dose Analysis): all enrolled participants who received first 2 doses of planned doses of mRNA-1273 vaccination in Part 3 open-label phase per schedule, received third dose in Third Dose Analysis, participants with HIV were not receiving HAART, had BD-Day 29 antibody assessment for the analysis endpoint, had no major protocol deviations that impact key or critical data, and had not receive off-study COVID-19 vaccination prior to BD-Day 29 visit.
| AU/mL | Part 3 (6-11 Years): BD mRNA-1273 25 µg |
|---|---|
| Baseline (Pre-dose 1) | 4659.5 (2918.7 to 7438.5) |
| Day 57 | 141758.0 (118762.4 to 169206.2) |
| Third Dose-Day 1 | 48176.2 (38955.2 to 59580.0) |
| Third Dose-Day 29 | 93436.4 (77735.5 to 112308.5) |
| Third Dose-Day 181 | 40271.7 (32950.9 to 49219.2) |
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ and values greater than ULOQ were replaced by ULOQ if actual values were not available. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer. PP Immunogenicity Subset: all enrolled participants who received planned doses of the study vaccine per schedule, had baseline SARS-CoV-2 status, had baseline and Day 57 antibody assessment for analysis endpoint, complied with immunogenicity window based on 2nd injection timing; had negative RT-PCR test for SARS-CoV-2 and negative serology test based on bAb specific to SARS-CoV-2 nucleocapsid protein at baseline, not receiving HAART in participants with HIV; and had no major protocol deviations that impacted key or critical data.
| titer | Part 1 (6-11 Years): mRNA-1273 50 µg | Part 1 (6-11 Years): mRNA-1273 100 µg | Part 1 (2-5 Years): mRNA-1273 25 µg | Part 1 (2-5 Years): mRNA-1273 50 µg | Part 1 (6-23 Months): mRNA-1273 25 µg | Part 2 (6-11 Years): mRNA-1273 50 µg |
|---|---|---|---|---|---|---|
| Day 1 | 9.3 (9.2 to 9.5) | 9.6 (8.9 to 10.3) | 9.3 (NA to NA) | 9.3 (NA to NA) | 9.6 (9.3 to 9.9) | 9.3 (NA to NA) |
| Day 57 | 1669.1 (1504.5 to 1851.6) | 1890.2 (1603.8 to 2227.7) | 1012.5 (848.2 to 1208.6) | 1845.9 (1600.5 to 2128.9) | 1782.6 (1542.0 to 2060.7) | 1618.3 (1460.0 to 1793.9) |
Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ and values greater than the ULOQ were replaced by ULOQ if actual values were not available. LLOQ was 10 AU/mL and ULOQ was 111433 AU/mL. Data are reported per Baseline SARS-CoV-2 status: Negative and Positive. PP Immunogenicity Subset: all enrolled participants who received planned doses of the study vaccine per schedule, had baseline SARS-CoV-2 status, had baseline and Day 57 antibody assessment for analysis endpoint, complied with immunogenicity window based on 2nd injection timing; had negative RT-PCR test for SARS-CoV-2 and negative serology test based on bAb specific to SARS-CoV-2 nucleocapsid protein at baseline in Part 2, not receiving HAART in participants with HIV; and had no major protocol deviations that impacted key or critical data.
| AU/mL | Part 2 (2-5 Years): mRNA-1273 25 µg | Part 2 (6-23 Months): mRNA-1273 25 µg | Part 3 (6-11 Years): Primary Series mRNA-1273 25 µg |
|---|---|---|---|
| Baseline SARS-CoV-2 (Negative): Day 1 | 7.9 (7.5 to 8.4) | 8.0 (7.5 to 8.5) | 21.5 (2.6 to 175.1) |
| Baseline SARS-CoV-2 (Positive): Day 1 | 175.3 (130.4 to 235.6) | 199.9 (109.2 to 365.9) | 177.5 (111.2 to 283.3) |
| Baseline SARS-CoV-2(Negative): Day 57 | 1398.1 (1271.9 to 1536.8) | 1760.8 (1609.7 to 1926.0) | 2140.6 (728.7 to 6288.7) |
| Baseline SARS-CoV-2 (Positive): Day 57 | 7430.0 (5188.4 to 10640.1) | 10411.6 (6712.1 to 16150.1) | 4592.9 (3470.7 to 6077.9) |
Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ and values greater than the ULOQ were replaced by ULOQ if actual values were not available. LLOQ was 10 AU/mL and ULOQ was 111433 AU/mL. PP Immunogenicity Subset (Booster Dose Analysis): all enrolled participants who received 2 doses of planned doses of mRNA-1273 vaccination in Part 1 open-label phase or Part 2 blinded phase per schedule, received booster dose in Booster Dose Analysis, not receiving HAART in participants with HIV, had a negative SARS-CoV-2 status at baseline (pre-dose 1 of mRNA-1273), had BD-Day 29 Ab assessment for the analysis endpoint, no major protocol deviations that impacted key or critical data, and had not received off-study COVID-19 vaccination prior to BD-Day 29 visit.
| AU/mL | Part 1 (6-23 Months): PS mRNA-1273 25 μg - BD 10 μg | Part 1 (2-5 Years): PS mRNA-1273 25 μg - BD 10 μg | Part 2 (6-11 Years): PS mRNA-1273 50 μg - BD 1273 25 μg | Part 1 (6-11 Years): PS mRNA-1273 50 μg - BD 25 μg |
|---|---|---|---|---|
| Baseline | 9.0 (8.2 to 9.9) | 12.8 (10.0 to 16.3) | 7.8 (7.1 to 8.6) | 9.3 (8.5 to 10.3) |
| Day 57 | 1557.1 (1294.2 to 1873.5) | 1275.0 (983.0 to 1653.8) | 1718.7 (1316.5 to 2243.7) | 1503.3 (1292.3 to 1748.7) |
| Day 209 | 448.6 (376.9 to 533.8) | 544.5 (343.1 to 864.0) | 790.7 (633.8 to 986.4) | 530.3 (432.5 to 650.2) |
| BD-Day 1 | 558.0 (408.5 to 762.2) | 447.2 (270.0 to 740.7) | 795.5 (640.8 to 987.5) | 627.9 (467.8 to 842.8) |
| BD-Day 29 | 6474.7 (5406.0 to 7754.8) | 5778.7 (4039.7 to 8266.4) | 5805.4 (5122.4 to 6579.4) | 6991.6 (6091.2 to 8025.0) |
Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ and values greater than the ULOQ were replaced by ULOQ if actual values were not available. LLOQ was 10 AU/mL and ULOQ was 111433 AU/mL. PP Immunogenicity Subset (Third Dose Analysis): all enrolled participants who received first 2 doses of planned doses of mRNA-1273 vaccination in Part 3 open-label phase per schedule, received third dose in Third Dose Analysis, not receiving HAART in participants with HIV, had BD-Day 29 antibody assessment for the analysis endpoint, had no major protocol deviations that impacted key or critical data, and had not received off-study COVID-19 vaccination prior to BD-Day 29 visit.
| AU/mL | Part 3 (6-11 Years): BD mRNA-1273 25 µg |
|---|---|
| Baseline | 120.0 (71.9 to 200.3) |
| Day 57 | 3775.0 (2767.5 to 5149.3) |
| Third Dose-Day 1 | 1839.1 (1279.8 to 2643.0) |
| Third Dose-Day 29 | 4616.6 (3669.4 to 5808.3) |
| Third Dose-Day 181 | 1432.5 (1038.6 to 1975.8) |
SARS-CoV-2 infection was defined in participants with negative SARS-CoV-2 at baseline: bAb level against SARS-CoV-2 nucleocapsid protein negative at Day 1, that became positive (as measured by Roche Elecsys) postbaseline; OR positive RT-PCR postbaseline. PP Set for Efficacy included all enrolled participants who received planned doses of study drug per schedule, complied with the 2nd injection timing, had no major protocol deviations that impacted key or critical efficacy data, and had a negative RT-PCR test for SARS-CoV-2 and negative serology test based on bAb specific to SARS-CoV-2 nucleocapsid protein at baseline.
| Participants | Part 2 (6-11 Years): Placebo | Part 2 (6-11 Years): mRNA-1273 50 µg | Part 2 (2-5 Years): Placebo | Part 2 (2-5 Years): mRNA-1273 25 µg | Part 2 (6-23 Months): Placebo | Part 2 (6-23 Months): mRNA-1273 25 µg |
|---|---|---|---|---|---|---|
| Part 2: Number of Participants With SARS-CoV-2 Infection Including Symptomatic and Asymptomatic Infection (by Serology and/or RT-PCR) | 14 | 13 | 178 | 330 | 94 | 198 |
Asymptomatic SARS-CoV-2 infection was identified by absence of symptoms and infections as detected by RT-PCR or serology tests: Absence of COVID-19 symptoms AND at least 1 from following: bAb level against SARS-CoV-2 nucleocapsid protein negative at Day 1 that became positive post-baseline, OR positive RT-PCR test post-baseline. PP Set for Efficacy included all enrolled participants who received planned doses of study drug per schedule, complied with the 2nd injection timing, had no major protocol deviations that impacted key or critical efficacy data, and had a negative RT-PCR test for SARS-CoV-2 and negative serology test based on bAb specific to SARS-CoV-2 nucleocapsid protein at baseline.
| Participants | Part 2 (6-11 Years): Placebo | Part 2 (6-11 Years): mRNA-1273 50 µg | Part 2 (2-5 Years): Placebo | Part 2 (2-5 Years): mRNA-1273 25 µg | Part 2 (6-23 Months): Placebo | Part 2 (6-23 Months): mRNA-1273 25 µg |
|---|---|---|---|---|---|---|
| Part 2: Number of Participants With Asymptomatic SARS-CoV-2 Infection, Measured by RT-PCR and/or bAb Levels Against SARS-CoV-2 Nucleocapsid Protein (by Roche Elecsys) | 10 | 10 | 55 | 124 | 21 | 70 |
A COVID-19 case was identified as a positive post-baseline RT-PCR test result together with at least 1 of following systemic symptoms: fever (≥ 38 degrees Celsius \[°C\]/≥ 100.4 degree Fahrenheit \[°F\]) or chills, fatigue, headache, myalgia, nasal congestion or rhinorrhea, new loss of taste or smell, sore throat, abdominal pain, diarrhoea, nausea/vomiting, poor appetite/poor feeding; or at least 1 of following respiratory signs/symptoms: cough, shortness of breath or difficulty breathing. PP Set for Efficacy included all enrolled participants who received planned doses of study drug per schedule, complied with the 2nd injection timing, had no major protocol deviations that impacted key or critical efficacy data, and had a negative RT-PCR test for SARS-CoV-2 and negative serology test based on bAb specific to SARS-CoV-2 nucleocapsid protein at baseline.
| Participants | Part 2 (6-11 Years): Placebo | Part 2 (6-11 Years): mRNA-1273 50 µg | Part 2 (2-5 Years): Placebo | Part 2 (2-5 Years): mRNA-1273 25 µg | Part 2 (6-23 Months): Placebo | Part 2 (6-23 Months): mRNA-1273 25 µg |
|---|---|---|---|---|---|---|
| Part 2: Number of Participants With Occurrence of COVID-19 (Per US Centers for Disease Control and Prevention [CDC] Case Definition of COVID-19) | 4 | 3 | 125 | 207 | 73 | 130 |
A death that occurred during the study or that came to the attention of the investigator during the study was reported to the Sponsor, whether or not it was considered related to study drug. The investigator assessed causality (that is, whether there is a reasonable possibility that the study drug caused the death). The relationship was characterized using the following classifications: Not related: There was not a reasonable possibility of a relationship to the study drug. The temporal sequence of the death relative to administration of the study drug was not reasonable AND/OR the death was more likely explained by a cause other than the study drug. Related: There was a reasonable possibility of a relationship to the study drug. There was evidence of exposure to the study drug. The temporal sequence of the death relative to the administration of the study drug was reasonable. The death was more likely explained by the study drug than by another cause.
| Participants | Part 1 (6-11 Years): mRNA-1273 50 µg | Part 1 (6-11 Years): mRNA-1273 100 µg | Part 1 (2-5 Years): mRNA-1273 25 µg | Part 1 (2-5 Years): mRNA-1273 50 µg | Part 1 (6-23 Months): mRNA-1273 25 µg | Part 2 (6-11 Years): Placebo | Part 2 (6-11 Years): mRNA-1273 50 µg | Part 2 (2-5 Years): Placebo | Part 2 (2-5 Years): mRNA-1273 25 µg | Part 2 (6-23 Months): Placebo | Part 2 (6-23 Months): mRNA-1273 25 µg | Part 3 (6-11 Years): Primary Series mRNA-1273 25 µg | Part 2(6-11 Yrs): PS PBO - mRNA-1273 50 μg (Crossover) | Part 2 (2-5 Years): PS PBO - mRNA-1273 25 μg (Crossover) | Part 2 (6-23 Months): PBO - mRNA-1273 25 μg (Crossover) | Part 3 (6-11 Years): BD mRNA-1273 25 µg | 6-11 Years: BD mRNA-1273 25 μg | 6-11 Yrs: BD mRNA-1273.214 25 μg | 6 Months-5 Yrs: BD mRNA-1273 10 μg | 6 Months-5 Yrs: BD mRNA-1273 25 μg | 6 Months-5 Yrs: BD mRNA-1273.214 10 μg | 6 Months-5 Yrs: BD mRNA-1273.214 25 μg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Deaths | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Deaths related to study drug | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Collected over Up to 2 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1 (6-11 Years): mRNA-1273 50 µg | 0/380 (0%) | 5/380 (1.3%) | 145/380 (38.2%) |
| Part 1 (6-11 Years): mRNA-1273 100 µg | 0/371 (0%) | 3/371 (0.8%) | 134/371 (36.1%) |
| Part 1 (2-5 Years): mRNA-1273 25 µg | 0/69 (0%) | 0/69 (0%) | 30/69 (43.5%) |
| Part 1 (2-5 Years): mRNA-1273 50 µg | 0/155 (0%) | 0/155 (0%) | 78/155 (50.3%) |
| Part 1 (6-23 Months): mRNA-1273 25 µg | 0/150 (0%) | 3/150 (2%) | 111/150 (74%) |
| Part 2 (6-11 Years): Placebo | 0/995 (0%) | 1/995 (0.1%) | 100/995 (10.1%) |
| Part 2 (6-11 Years): mRNA-1273 50 µg | 0/3,007 (0%) | 22/3,007 (0.7%) | 573/3,007 (19.1%) |
| Part 2 (2-5 Years): Placebo | 0/1,007 (0%) | 3/1,007 (0.3%) | 356/1,007 (35.4%) |
| Part 2 (2-5 Years): mRNA-1273 25 µg | 0/3,031 (0%) | 32/3,031 (1.1%) | 1,341/3,031 (44.2%) |
| Part 2 (6-23 Months): Placebo | 0/666 (0%) | 7/666 (1.1%) | 317/666 (47.6%) |
| Part 2 (6-23 Months): mRNA-1273 25 µg | 0/1,994 (0%) | 45/1,994 (2.3%) | 1,095/1,994 (54.9%) |
| Part 3 (6-11 Years): Primary Series mRNA-1273 25 µg | 0/90 (0%) | 1/90 (1.1%) | 9/90 (10%) |
| Part 2(6-11 Yrs): PS PBO - mRNA-1273 50 μg (Crossover) | 0/701 (0%) | 3/701 (0.4%) | 64/701 (9.1%) |
| Part 2 (2-5 Years): PS PBO - mRNA-1273 25 μg (Crossover) | 0/640 (0%) | 8/640 (1.3%) | 58/640 (9.1%) |
| Part 2 (6-23 Months): PBO - mRNA-1273 25 μg (Crossover) | 0/444 (0%) | 4/444 (0.9%) | 62/444 (14%) |
| Part 3 (6-11 Years): BD mRNA-1273 25 µg | 0/70 (0%) | 0/70 (0%) | 4/70 (5.7%) |
| 6-11 Years: BD mRNA-1273 25 μg | 0/2,766 (0%) | 12/2,766 (0.4%) | 468/2,766 (16.9%) |
| 6-11 Yrs: BD mRNA-1273.214 25 μg | 0/184 (0%) | 0/184 (0%) | 28/184 (15.2%) |
| 6 Months-5 Yrs: BD mRNA-1273 10 μg | 0/212 (0%) | 1/212 (0.5%) | 56/212 (26.4%) |
| 6 Months-5 Yrs: BD mRNA-1273 25 μg | 0/89 (0%) | 1/89 (1.1%) | 20/89 (22.5%) |
| 6 Months-5 Yrs: BD mRNA-1273.214 10 μg | 1/2,771 (0%) | 23/2,771 (0.8%) | 655/2,771 (23.6%) |
| 6 Months-5 Yrs: BD mRNA-1273.214 25 μg | 0/28 (0%) | 0/28 (0%) | 4/28 (14.3%) |
| Event | Part 1 (6-11 Years): mRNA-1273 50 µg | Part 1 (6-11 Years): mRNA-1273 100 µg | Part 1 (2-5 Years): mRNA-1273 25 µg | Part 1 (2-5 Years): mRNA-1273 50 µg | Part 1 (6-23 Months): mRNA-1273 25 µg | Part 2 (6-11 Years): Placebo | Part 2 (6-11 Years): mRNA-1273 50 µg | Part 2 (2-5 Years): Placebo | Part 2 (2-5 Years): mRNA-1273 25 µg | Part 2 (6-23 Months): Placebo | Part 2 (6-23 Months): mRNA-1273 25 µg | Part 3 (6-11 Years): Primary Series mRNA-1273 25 µg | Part 2(6-11 Yrs): PS PBO - mRNA-1273 50 μg (Crossover) | Part 2 (2-5 Years): PS PBO - mRNA-1273 25 μg (Crossover) | Part 2 (6-23 Months): PBO - mRNA-1273 25 μg (Crossover) | Part 3 (6-11 Years): BD mRNA-1273 25 µg | 6-11 Years: BD mRNA-1273 25 μg | 6-11 Yrs: BD mRNA-1273.214 25 μg | 6 Months-5 Yrs: BD mRNA-1273 10 μg | 6 Months-5 Yrs: BD mRNA-1273 25 μg | 6 Months-5 Yrs: BD mRNA-1273.214 10 μg | 6 Months-5 Yrs: BD mRNA-1273.214 25 μg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ConstipationGastrointestinal disorders | 0/380 | 1/371 | 0/69 | 0/155 | 0/150 | 0/995 | 0/3007 | 0/1007 | 1/3031 | 0/666 | 0/1994 | 0/90 | 0/701 | 0/640 | 0/444 | 0/70 | 0/2766 | 0/184 | 0/212 | 1/89 | 0/2771 | 0/28 |
| BronchospasmRespiratory, thoracic and mediastinal disorders | 0/380 | 0/371 | 0/69 | 0/155 | 0/150 | 0/995 | 0/3007 | 0/1007 | 0/3031 | 0/666 | 1/1994 | 1/90 | 0/701 | 0/640 | 0/444 | 0/70 | 0/2766 | 0/184 | 0/212 | 0/89 | 0/2771 | 0/28 |
| Anaphylactic reactionImmune system disorders | 0/380 | 0/371 | 0/69 | 0/155 | 1/150 | 0/995 | 0/3007 | 0/1007 | 0/3031 | 0/666 | 0/1994 | 0/90 | 0/701 | 0/640 | 0/444 | 0/70 | 0/2766 | 0/184 | 0/212 | 0/89 | 0/2771 | 0/28 |
| Rhinovirus infectionInfections and infestations | 0/380 | 0/371 | 0/69 | 0/155 | 1/150 | 0/995 | 0/3007 | 1/1007 | 2/3031 | 1/666 | 3/1994 | 0/90 | 0/701 | 0/640 | 0/444 | 0/70 | 2/2766 | 0/184 | 0/212 | 0/89 | 0/2771 | 0/28 |
| Febrile convulsionNervous system disorders | 0/380 | 0/371 | 0/69 | 0/155 | 1/150 | 0/995 | 0/3007 | 0/1007 | 0/3031 | 0/666 | 3/1994 | 0/90 | 0/701 | 1/640 | 0/444 | 0/70 | 1/2766 | 0/184 | 0/212 | 0/89 | 0/2771 | 0/28 |
| BronchiolitisInfections and infestations | 0/380 | 0/371 | 0/69 | 0/155 | 0/150 | 0/995 | 0/3007 | 0/1007 | 1/3031 | 4/666 | 8/1994 | 0/90 | 0/701 | 1/640 | 1/444 | 0/70 | 0/2766 | 0/184 | 0/212 | 0/89 | 2/2771 | 0/28 |
| AppendicitisInfections and infestations | 2/380 | 0/371 | 0/69 | 0/155 | 0/150 | 0/995 | 4/3007 | 0/1007 | 0/3031 | 0/666 | 0/1994 | 0/90 | 1/701 | 0/640 | 0/444 | 0/70 | 2/2766 | 0/184 | 0/212 | 0/89 | 0/2771 | 0/28 |
| Pharyngeal abscessInfections and infestations | 0/380 | 0/371 | 0/69 | 0/155 | 0/150 | 0/995 | 0/3007 | 0/1007 | 0/3031 | 0/666 | 0/1994 | 0/90 | 0/701 | 0/640 | 0/444 | 0/70 | 0/2766 | 0/184 | 1/212 | 0/89 | 0/2771 | 0/28 |
| Streptococcal infectionInfections and infestations | 0/380 | 0/371 | 0/69 | 0/155 | 0/150 | 0/995 | 0/3007 | 0/1007 | 0/3031 | 0/666 | 0/1994 | 0/90 | 0/701 | 0/640 | 0/444 | 0/70 | 0/2766 | 0/184 | 1/212 | 0/89 | 0/2771 | 0/28 |
| Respiratory syncytial virus infectionInfections and infestations | 0/380 | 0/371 | 0/69 | 0/155 | 0/150 | 0/995 | 0/3007 | 0/1007 | 2/3031 | 0/666 | 3/1994 | 0/90 | 0/701 | 2/640 | 0/444 | 0/70 | 0/2766 | 0/184 | 0/212 | 0/89 | 2/2771 | 0/28 |
| Event | Part 1 (6-11 Years): mRNA-1273 50 µg | Part 1 (6-11 Years): mRNA-1273 100 µg | Part 1 (2-5 Years): mRNA-1273 25 µg | Part 1 (2-5 Years): mRNA-1273 50 µg | Part 1 (6-23 Months): mRNA-1273 25 µg | Part 2 (6-11 Years): Placebo | Part 2 (6-11 Years): mRNA-1273 50 µg | Part 2 (2-5 Years): Placebo | Part 2 (2-5 Years): mRNA-1273 25 µg | Part 2 (6-23 Months): Placebo | Part 2 (6-23 Months): mRNA-1273 25 µg | Part 3 (6-11 Years): Primary Series mRNA-1273 25 µg | Part 2(6-11 Yrs): PS PBO - mRNA-1273 50 μg (Crossover) | Part 2 (2-5 Years): PS PBO - mRNA-1273 25 μg (Crossover) | Part 2 (6-23 Months): PBO - mRNA-1273 25 μg (Crossover) | Part 3 (6-11 Years): BD mRNA-1273 25 µg | 6-11 Years: BD mRNA-1273 25 μg | 6-11 Yrs: BD mRNA-1273.214 25 μg | 6 Months-5 Yrs: BD mRNA-1273 10 μg | 6 Months-5 Yrs: BD mRNA-1273 25 μg | 6 Months-5 Yrs: BD mRNA-1273.214 10 μg | 6 Months-5 Yrs: BD mRNA-1273.214 25 μg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 56/380 | 50/371 | 9/69 | 45/155 | 37/150 | 47/995 | 284/3007 | 190/1007 | 630/3031 | 146/666 | 512/1994 | 9/90 | 59/701 | 39/640 | 31/444 | 4/70 | 164/2766 | 2/184 | 24/212 | 6/89 | 132/2771 | 0/28 |
| PyrexiaGeneral disorders | 17/380 | 21/371 | 2/69 | 23/155 | 40/150 | 10/995 | 83/3007 | 49/1007 | 222/3031 | 57/666 | 194/1994 | 0/90 | 0/701 | 0/640 | 0/444 | 0/70 | 0/2766 | 0/184 | 0/212 | 0/89 | 0/2771 | 0/28 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 12/380 | 26/371 | 6/69 | 13/155 | 34/150 | 28/995 | 107/3007 | 70/1007 | 250/3031 | 53/666 | 173/1994 | 0/90 | 0/701 | 0/640 | 0/444 | 0/70 | 0/2766 | 0/184 | 0/212 | 0/89 | 0/2771 | 0/28 |
| CoughRespiratory, thoracic and mediastinal disorders | 23/380 | 34/371 | 8/69 | 12/155 | 27/150 | 26/995 | 136/3007 | 69/1007 | 262/3031 | 43/666 | 130/1994 | 0/90 | 0/701 | 0/640 | 0/444 | 0/70 | 0/2766 | 0/184 | 0/212 | 0/89 | 0/2771 | 0/28 |
| Otitis mediaInfections and infestations | 5/380 | 1/371 | 3/69 | 7/155 | 24/150 | 2/995 | 31/3007 | 42/1007 | 231/3031 | 54/666 | 258/1994 | 0/90 | 5/701 | 23/640 | 38/444 | 0/70 | 46/2766 | 1/184 | 16/212 | 5/89 | 225/2771 | 1/28 |
| Ear infectionInfections and infestations | 1/380 | 9/371 | 4/69 | 3/155 | 19/150 | 3/995 | 22/3007 | 47/1007 | 237/3031 | 64/666 | 249/1994 | 0/90 | 0/701 | 0/640 | 0/444 | 0/70 | 37/2766 | 2/184 | 10/212 | 3/89 | 141/2771 | 2/28 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 27/380 | 34/371 | 5/69 | 5/155 | 18/150 | 0/995 | 0/3007 | 0/1007 | 0/3031 | 0/666 | 0/1994 | 0/90 | 0/701 | 0/640 | 0/444 | 0/70 | 0/2766 | 0/184 | 0/212 | 0/89 | 0/2771 | 0/28 |
| TeethingGastrointestinal disorders | 0/380 | 0/371 | 0/69 | 0/155 | 15/150 | 0/995 | 1/3007 | 7/1007 | 9/3031 | 39/666 | 109/1994 | 0/90 | 0/701 | 0/640 | 0/444 | 0/70 | 0/2766 | 0/184 | 0/212 | 0/89 | 0/2771 | 0/28 |
| Otitis media acuteInfections and infestations | 0/380 | 3/371 | 1/69 | 2/155 | 15/150 | 1/995 | 12/3007 | 16/1007 | 84/3031 | 18/666 | 113/1994 | 0/90 | 0/701 | 0/640 | 0/444 | 0/70 | 0/2766 | 0/184 | 0/212 | 0/89 | 0/2771 | 0/28 |
| InfluenzaInfections and infestations | 0/380 | 0/371 | 0/69 | 0/155 | 0/150 | 0/995 | 0/3007 | 0/1007 | 0/3031 | 0/666 | 0/1994 | 0/90 | 0/701 | 0/640 | 0/444 | 0/70 | 132/2766 | 18/184 | 6/212 | 3/89 | 102/2771 | 1/28 |
Safety Set of Part 1 and Part 3 included all dosed participants and of Part 2 included all randomized participants who received any study injection. Study mRNA-1273-P301 (P301) (NCT04470427) mRNA-1273 100 μg: PPIS of randomly selected participants from study P301 aged 18-25 meeting pre-specified criteria.
| Age, Customized(Participants) | Part 1 (6-11 Years): mRNA-1273 50 µg | Part 1 (6-11 Years): mRNA-1273 100 µg | Part 1 (2-5 Years): mRNA-1273 25 µg | Part 1 (2-5 Years): mRNA-1273 50 µg | Part 1 (6-23 Months): mRNA-1273 25 µg | Part 2 (6-11 Years): Placebo | Part 2 (6-11 Years): mRNA-1273 50 µg | Part 2 (2-5 Years): Placebo | Part 2 (2-5 Years): mRNA-1273 25 µg | Part 2 (6-23 Months): Placebo | Part 2 (6-23 Months): mRNA-1273 25 µg | Part 3 (6-11 Years): Primary Series mRNA-1273 25 µg | Study mRNA-1273-P301 (NCT04470427) mRNA-1273 100 μg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age Categorical Data for Participants Enrolled in Study mRNA-1273-P204 — Infants and toddlers (28 days - 23 months) | 0 | 0 | 0 | 0 | 150 | 0 | 0 | 11 | 18 | 669 | 1989 | 0 | 0 | 2837 |
| Age Categorical Data for Participants Enrolled in Study mRNA-1273-P204 — Children (2 - 11 years) | 380 | 371 | 75 | 149 | 0 | 1004 | 3011 | 997 | 3022 | 0 | 6 | 90 | 0 | 9105 |
| Age Categorical Data for Participants Enrolled in Study mRNA-1273-P204 — Adults (between 18 and 64 years) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Age Categorical Data for Participants Enrolled in Study mRNA-1273-P301 — Infants and toddlers (28 days - 23 months) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Age Categorical Data for Participants Enrolled in Study mRNA-1273-P301 — Children (2 - 11 years) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Age Categorical Data for Participants Enrolled in Study mRNA-1273-P301 — Adults (between 18 and 64 years) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 296 | 296 |
| Sex: Female, Male(Participants) | Part 1 (6-11 Years): mRNA-1273 50 µg | Part 1 (6-11 Years): mRNA-1273 100 µg | Part 1 (2-5 Years): mRNA-1273 25 µg | Part 1 (2-5 Years): mRNA-1273 50 µg | Part 1 (6-23 Months): mRNA-1273 25 µg | Part 2 (6-11 Years): Placebo | Part 2 (6-11 Years): mRNA-1273 50 µg | Part 2 (2-5 Years): Placebo | Part 2 (2-5 Years): mRNA-1273 25 µg | Part 2 (6-23 Months): Placebo | Part 2 (6-23 Months): mRNA-1273 25 µg | Part 3 (6-11 Years): Primary Series mRNA-1273 25 µg | Study mRNA-1273-P301 (NCT04470427) mRNA-1273 100 μg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sex Data for Participants Enrolled in Study mRNA-1273-P204 — Female | 185 | 199 | 39 | 69 | 67 | 516 | 1456 | 498 | 1490 | 341 | 981 | 34 | 0 | 5875 |
| Sex Data for Participants Enrolled in Study mRNA-1273-P204 — Male | 195 | 172 | 36 | 80 | 83 | 488 | 1555 | 510 | 1550 | 328 | 1014 | 56 | 0 | 6067 |
| Sex Data for Participants Enrolled in Study mRNA-1273-P301 — Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 153 | 153 |
| Sex Data for Participants Enrolled in Study mRNA-1273-P301 — Male | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 143 | 143 |
| Ethnicity (NIH/OMB)(Participants) | Part 1 (6-11 Years): mRNA-1273 50 µg | Part 1 (6-11 Years): mRNA-1273 100 µg | Part 1 (2-5 Years): mRNA-1273 25 µg | Part 1 (2-5 Years): mRNA-1273 50 µg | Part 1 (6-23 Months): mRNA-1273 25 µg | Part 2 (6-11 Years): Placebo | Part 2 (6-11 Years): mRNA-1273 50 µg | Part 2 (2-5 Years): Placebo | Part 2 (2-5 Years): mRNA-1273 25 µg | Part 2 (6-23 Months): Placebo | Part 2 (6-23 Months): mRNA-1273 25 µg | Part 3 (6-11 Years): Primary Series mRNA-1273 25 µg | Study mRNA-1273-P301 (NCT04470427) mRNA-1273 100 μg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ethnicity Data for Participants Enrolled in Study mRNA-1273-P204 — Hispanic or Latino | 72 | 69 | 24 | 17 | 15 | 183 | 562 | 142 | 429 | 94 | 257 | 29 | 0 | 1893 |
| Ethnicity Data for Participants Enrolled in Study mRNA-1273-P204 — Not Hispanic or Latino | 304 | 296 | 51 | 129 | 133 | 811 | 2421 | 857 | 2593 | 568 | 1719 | 58 | 0 | 9940 |
| Ethnicity Data for Participants Enrolled in Study mRNA-1273-P204 — Unknown or Not Reported | 4 | 6 | 0 | 3 | 2 | 10 | 28 | 9 | 18 | 7 | 19 | 3 | 0 | 109 |
| Ethnicity Data for Participants Enrolled in Study mRNA-1273-P301 — Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 78 | 78 |
| Ethnicity Data for Participants Enrolled in Study mRNA-1273-P301 — Not Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 216 | 216 |
| Ethnicity Data for Participants Enrolled in Study mRNA-1273-P301 — Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 |
| Race/Ethnicity, Customized(Participants) | Part 1 (6-11 Years): mRNA-1273 50 µg | Part 1 (6-11 Years): mRNA-1273 100 µg | Part 1 (2-5 Years): mRNA-1273 25 µg | Part 1 (2-5 Years): mRNA-1273 50 µg | Part 1 (6-23 Months): mRNA-1273 25 µg | Part 2 (6-11 Years): Placebo | Part 2 (6-11 Years): mRNA-1273 50 µg | Part 2 (2-5 Years): Placebo | Part 2 (2-5 Years): mRNA-1273 25 µg | Part 2 (6-23 Months): Placebo | Part 2 (6-23 Months): mRNA-1273 25 µg | Part 3 (6-11 Years): Primary Series mRNA-1273 25 µg | Study mRNA-1273-P301 (NCT04470427) mRNA-1273 100 μg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Race Data for Participants Enrolled in Study mRNA-1273-P204 — White | 266 | 284 | 54 | 128 | 124 | 676 | 1960 | 793 | 2307 | 527 | 1568 | 48 | 0 | 8735 |
| Race Data for Participants Enrolled in Study mRNA-1273-P204 — Black or African American | 34 | 13 | 3 | 7 | 3 | 94 | 310 | 38 | 142 | 18 | 62 | 37 | 0 | 761 |
| Race Data for Participants Enrolled in Study mRNA-1273-P204 — Asian | 28 | 25 | 8 | 3 | 7 | 100 | 297 | 51 | 191 | 38 | 94 | 2 | 0 | 844 |
| Race Data for Participants Enrolled in Study mRNA-1273-P204 — American Indian or Alaska Native | 0 | 2 | 0 | 0 | 1 | 3 | 15 | 3 | 11 | 0 | 7 | 2 | 0 | 44 |
| Race Data for Participants Enrolled in Study mRNA-1273-P204 — Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 0 | 0 | 0 | 4 | 3 | 5 | 0 | 0 | 0 | 0 | 13 |
| Race Data for Participants Enrolled in Study mRNA-1273-P204 — Other | 3 | 10 | 7 | 1 | 3 | 22 | 62 | 16 | 43 | 7 | 33 | 0 | 0 | 207 |
| Race Data for Participants Enrolled in Study mRNA-1273-P204 — Multiple | 39 | 31 | 3 | 10 | 11 | 98 | 330 | 100 | 324 | 76 | 215 | 0 | 0 | 1237 |
| Race Data for Participants Enrolled in Study mRNA-1273-P204 — Not Reported | 9 | 4 | 0 | 0 | 0 | 10 | 23 | 4 | 13 | 2 | 11 | 1 | 0 | 77 |
| Race Data for Participants Enrolled in Study mRNA-1273-P204 — Unknown | 0 | 2 | 0 | 0 | 1 | 1 | 10 | 0 | 4 | 1 | 5 | 0 | 0 | 24 |
| Race Data for Participants Enrolled in Study mRNA-1273-P301 — White | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 207 | 207 |
| Race Data for Participants Enrolled in Study mRNA-1273-P301 — Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 29 | 29 |
| Race Data for Participants Enrolled in Study mRNA-1273-P301 — Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 30 | 30 |
| Race Data for Participants Enrolled in Study mRNA-1273-P301 — American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 |
| Race Data for Participants Enrolled in Study mRNA-1273-P301 — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 |
| Race Data for Participants Enrolled in Study mRNA-1273-P301 — Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 8 |
| Race Data for Participants Enrolled in Study mRNA-1273-P301 — Multiple | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14 | 14 |
| Race Data for Participants Enrolled in Study mRNA-1273-P301 — Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 |
| Race Data for Participants Enrolled in Study mRNA-1273-P301 — Unknown | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2021 to primary completion in Mar 2024, 36 months.
Results were first posted in Jun 2025, 1 year 2 months after primary completion.
Of 73 industry-sponsored phase 2/3 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's 36 months is above that.
Counting every sponsor, half of 168 studies reached it within 11 months; a quarter within 5 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 2019-nCoV Vaccine mRNA-1273